- Home
- JBGS vs ETNB Comparison
JBGS vs ETNB Comparison
Compare JBGS & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- ETNB
- Stock Information
- Founded
- JBGS 2016
- ETNB 2018
- Country
- JBGS United States
- ETNB United States
- Employees
- JBGS N/A
- ETNB N/A
- Industry
- JBGS Real Estate Investment Trusts
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- JBGS Real Estate
- ETNB Health Care
- Exchange
- JBGS Nasdaq
- ETNB Nasdaq
- Market Cap
- JBGS 1.3B
- ETNB 1.5B
- IPO Year
- JBGS 2017
- ETNB 2019
- Fundamental
- Price
- JBGS $17.07
- ETNB $10.12
- Analyst Decision
- JBGS Sell
- ETNB Strong Buy
- Analyst Count
- JBGS 2
- ETNB 8
- Target Price
- JBGS $16.00
- ETNB $26.43
- AVG Volume (30 Days)
- JBGS 1.7M
- ETNB 2.2M
- Earning Date
- JBGS 07-29-2025
- ETNB 08-04-2025
- Dividend Yield
- JBGS 4.10%
- ETNB N/A
- EPS Growth
- JBGS N/A
- ETNB N/A
- EPS
- JBGS N/A
- ETNB N/A
- Revenue
- JBGS $520,825,000.00
- ETNB N/A
- Revenue This Year
- JBGS N/A
- ETNB N/A
- Revenue Next Year
- JBGS $2.71
- ETNB N/A
- P/E Ratio
- JBGS N/A
- ETNB N/A
- Revenue Growth
- JBGS N/A
- ETNB N/A
- 52 Week Low
- JBGS $13.28
- ETNB $4.16
- 52 Week High
- JBGS $18.86
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- JBGS 45.07
- ETNB 58.34
- Support Level
- JBGS $16.66
- ETNB $9.45
- Resistance Level
- JBGS $17.64
- ETNB $10.34
- Average True Range (ATR)
- JBGS 0.56
- ETNB 0.52
- MACD
- JBGS -0.17
- ETNB -0.07
- Stochastic Oscillator
- JBGS 16.14
- ETNB 69.34
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).